A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer  

作　　者：Hiroshi Kobayashi Chiharu Yoshimoto Sho Matsubara Hiroshi Shigetomi Shogo Imanaka 

机构地区：[1]Department of Gynecology and Reproductive Medicine,Ms.Clinic MayOne,Kashihara 634-0813,Japan [2]Department of Obstetrics and Gynecology,Nara Medical University,Kashihara 634-8522,Japan [3]Department of Obstetrics and Gynecology,Nara Prefecture General Medical Center,Nara 630-8581,Japan [4]Department of Medicine,Kei Oushin Clinic,Nishinomiya 663-8184,Japan [5]Department of Gynecology and Reproductive Medicine,Aska Ladies Clinic,Nara 634-0001,Japan

出　　处：《Cancer Drug Resistance》2023年第3期547-566,共20页癌症耐药（英文）

基　　金：supported by Japan Society for the Promotion of Science,Japan(Grant Number:23K08806).

摘　　要：Cancer cells adapt to environmental changes and alter their metabolic pathways to promote survival and proliferation. Metabolic reprogramming not only allows tumor cells to maintain a reduction-oxidation balance by rewiring resources for survival, but also causes nutrient addiction or metabolic vulnerability. Ferroptosis is a form of regulated cell death characterized by the iron-dependent accumulation of lipid peroxides. Excess iron in ovarian cancer amplifies free oxidative radicals and drives the Fenton reaction, thereby inducing ferroptosis. However, ovarian cancer is characterized by ferroptosis resistance. Therefore, the induction of ferroptosis is an exciting new targeted therapy for ovarian cancer. In this review, potential metabolic pathways targeting ferroptosis were summarized to promote anticancer effects, and current knowledge and future perspectives on ferroptosis for ovarian cancer therapy were discussed. Two therapeutic strategies were highlighted in this review: directly inducing the ferroptosis pathway and targeting metabolic vulnerabilities that affect ferroptosis. The overexpression of SLC7A11, a cystine/glutamate antiporter SLC7A11 (also known as xCT), is involved in the suppression of ferroptosis. xCT inhibition by ferroptosis inducers (e.g., erastin) can promote cell death when carbon as an energy source of glucose, glutamine, or fatty acids is abundant. On the contrary, xCT regulation has been reported to be highly dependent on the metabolic vulnerability. Drugs that target intrinsic metabolic vulnerabilities (e.g., GLUT1 inhibitors, PDK4 inhibitors, or glutaminase inhibitors) predispose cancer cells to death, which is triggered by decreased nicotinamide adenine dinucleotide phosphate generation or increased reactive oxygen species accumulation. Therefore, therapeutic approaches that either directly inhibit the xCT pathway or target metabolic vulnerabilities may be effective in overcoming ferroptosis resistance. Real-time monitoring of changes in metabolic pathways may aid in selecting per

关 键 词：Ferroptosis GLUTAMINOLYSIS GLYCOLYSIS metabolic vulnerability ovarian cancer pentose phosphate pathway 

分 类 号：R730.5[医药卫生—肿瘤]